Jeffrey Simmons, CEO of Elanco (ELAN), discusses their latest quarter as the stock hits a 52-week low after earnings. He also talks about their new partnership with Medgene for a bird flu vaccine for cattle, which is in the final stages of USDA approval. He adds that they sold their aqua business to pay down debt, and says the “quality of growth” of Elanco should be an investor focus.